STEPHEN DAVIS - 23 Feb 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
23 Feb 2023
Net transactions value
-$72,322
Form type
4
Filing time
27 Feb 2023, 20:00:28 UTC
Previous filing
10 Jan 2023
Next filing
07 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +10,945 +13% 95,578 23 Feb 2023 Direct F1
transaction ACAD Common Stock Sale $72,322 -3,851 -4% $18.78 91,727 24 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -10,945 -33% $0.000000 21,892 23 Feb 2023 Common Stock 10,945 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The restricted stock units vest in four equal annual installments beginning February 23, 2022.